News | Nanologica

Nanologica tar order från insulintillverkare för produktion

11 August, 2022

Nanologica AB (publ) har tagit en order på bolagets silika för preparativ kromatografi för utvärdering i produktionsskala, från en av världens största tillverkare av insulin. Om produkterna motsvarar kundens förväntningar förväntar sig bolaget kommersiella leveranser inom ett år. Nanologica har bearbetat kunder inom preparativ kromatografi sedan 2016 och ett flertal kunder har framgångsrikt utvärderat bolagets silika för preparativ kromatografi, NLAB Saga®, i olika steg. Nanologica har under en längre tid fört dialog med en av

Nanologica Expands Management Team for Increased Focus on Chromatography

10 August, 2022

Nanologica AB (publ) has expanded its management team with Katarina Alenäs, SVP Chromatography, as part of intensifying the company’s efforts within preparative chromatography. Katarina Alenäs took up her position as SVP Chromatograhy at Nanologica in the beginning of March, and most recently came from a role as Business Team Manager Sweden and Finland, Country General Manager Sweden and chairman of the board of Agilent Technologies Sweden AB. Katarina has a solid background and a strong

Nanologica utökar ledningsgruppen för stärkt fokus på kromatografi

10 August, 2022

Nanologica AB (publ) utökar sin ledningsgrupp med Katarina Alenäs, SVP Chromatography, som ett led i att bolagets satsning på preparativ kromatografi intensifieras. Katarina Alenäs tillträdde sin position som SVP Chromatography hos Nanologica i början av mars och kom närmast från en roll som Business Team Manager Sweden and Finland, Country General Manager Sweden samt styrelseordförande i Agilent Technologies Sweden AB. Katarina har en gedigen bakgrund och ett starkt nätverk inom kromatografiområdet, ett område hon har

Nanologica takes out loan of MSEK 20 within agreed credit facility

27 June, 2022

Nanologica AB (publ) has taken out a loan of MSEK 20 from the credit facility agreed in January with Flerie Invest AB. The loan is taken out to cover the company's temporary financial needs pending expected cash flows from the operations in preparative chromatography. After this loan, the credit facility has been used in full. Parts of the proceeds will be used to repay a loan from a private financier of MSEK 10 that expires

Nanologica upptar lån om 20 MSEK inom avtalad kreditfacilitet

27 June, 2022

Nanologica AB (publ) har upptagit ett lån om 20 MSEK ur den kreditfacilitet som i januari avtalades med Flerie Invest AB. Lånet upptas i syfte att överbrygga bolagets tillfälliga finansiella behov i väntan på förväntade kassaflöden från verksamheten inom preparativ kromatografi. Efter lånet har hela kreditfaciliteten nyttjats. Delar av likviden kommer att användas för att betala tillbaka ett lån från en privat finansiär om 10 MSEK som löper ut den 1 juli 2022 och som

Bulletin from the Annual General Meeting of Nanologica AB (publ)

2 June, 2022

Today June 2nd, 2022, Nanologica AB (publ) held its annual general meeting for the financial year 2021, where the following resolutions were passed. Adoption of income statement and balance sheet for the financial year 2021 and disposition of result The annual general meeting adopted the income statement and balance sheet for the company and for the group in accordance with the presented accounting documents, and resolved, in accordance with the board's proposal, that the accumulated

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.